Unknown

Dataset Information

0

IL-11 is required for A1 adenosine receptor-mediated protection against ischemic AKI.


ABSTRACT: A1 adenosine receptor activation ameliorates ischemic AKI through the induction of renal proximal tubular sphingosine kinase-1. However, systemic adverse effects may limit A1 adenosine receptor-based therapy for ischemic AKI, indicating a need to identify alternative therapeutic targets within this pathway. Here, we evaluated the function of renal proximal tubular IL-11, a clinically approved hematopoietic cytokine, in A1 adenosine receptor-mediated induction of sphingosine kinase-1 and renal protection. Treatment of human proximal tubule epithelial (HK-2) cells with a selective A1 adenosine receptor agonist, chloro-N(6)-cyclopentyladenosine (CCPA), induced the expression of IL-11 mRNA and protein in an extracellular signal-regulated kinase-dependent manner, and administration of CCPA in mice induced renal synthesis of IL-11. Pretreatment with CCPA protected against renal ischemia-reperfusion injury in wild-type mice, but not in IL-11 receptor-deficient mice. Administration of an IL-11-neutralizing antibody abolished the renal protection provided by CCPA. Similarly, CCPA did not induce renal IL-11 expression or protect against renal ischemia-reperfusion injury in mice lacking the renal proximal tubular A1 adenosine receptor. Finally, treatment with CCPA induced sphingosine kinase-1 in HK-2 cells and wild-type mice, but not in IL-11 receptor-deficient or renal proximal tubule A1 adenosine receptor-deficient mice. Taken together, these results suggest that induction of renal proximal tubule IL-11 is a critical intermediary in A1 adenosine receptor-mediated renal protection that warrants investigation as a novel therapeutic target for the treatment of ischemic AKI.

SUBMITTER: Kim JY 

PROVIDER: S-EPMC3785280 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

IL-11 is required for A1 adenosine receptor-mediated protection against ischemic AKI.

Kim Joo Yun JY   Kim Mihwa M   Ham Ahrom A   Brown Kevin M KM   Greene Robert W RW   D'Agati Vivette D VD   Lee H Thomas HT  

Journal of the American Society of Nephrology : JASN 20130627 10


A1 adenosine receptor activation ameliorates ischemic AKI through the induction of renal proximal tubular sphingosine kinase-1. However, systemic adverse effects may limit A1 adenosine receptor-based therapy for ischemic AKI, indicating a need to identify alternative therapeutic targets within this pathway. Here, we evaluated the function of renal proximal tubular IL-11, a clinically approved hematopoietic cytokine, in A1 adenosine receptor-mediated induction of sphingosine kinase-1 and renal pr  ...[more]

Similar Datasets

| S-EPMC7423360 | biostudies-literature
| S-EPMC3582209 | biostudies-literature
2013-09-05 | E-GEOD-44925 | biostudies-arrayexpress
| S-EPMC3055460 | biostudies-literature
| S-EPMC3443517 | biostudies-literature
| S-EPMC4349929 | biostudies-literature
2013-09-05 | GSE44925 | GEO
| S-EPMC4824453 | biostudies-literature
| S-EPMC7959549 | biostudies-literature
2019-07-05 | MTBLS856 | MetaboLights